Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes and obesity. Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is a …

www.alzforum.org

Dec 17, 2025 · Background NT-0796 is an oral, brain-penetrant inhibitor of inflammasomes that contain NLRP3, aka nod-like receptor family pyrin domain-containing protein 3. …

Lee TS, Park EJ, Choi M, Oh HS, An Y, Kim T, Kim TH, Shin BS, Shin S. Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain …

Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Epub 2019 Apr 12 PubMed.

Dec 1, 2023 · Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. …

Rubin R. Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?. JAMA. 2024 May 14;331 (18):1519-1521. PubMed.

Scheltens P, Atri A, Feldman H, Hansson O, Knop F, Sano M, Dethlefsen C, Johannsen P, León T, Hansen CT, Cummings J. Baseline Characteristics from Evoke and Evoke+: Two Phase 3 …

May 14, 2024 · Lixisenatide is one of four GLP-1 mimetics being tested for Alzheimer’s or Parkinson’s diseases. It is a 44-amino acid peptide closely related to exenatide (Leon et al., …

Jan 8, 2025 · Ortiz GU, de Freitas EC. Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging. Ageing Res Rev. 2024 Dec;102:102582. Epub 2024 Nov 14 …